Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOLF Triple Drug Therapy for Lymphatic Filariasis
NCT02899936Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Open-label trial of ivermectin in lymphatic filariasis (LF) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Treatment-related adverse events at 7 days. Started Jul 2016; status: completed.
02
Drugs
ivermectin
03
Conditions
lymphatic filariasis (LF)
Beyond the preview
Go deeper on NCT02899936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899936.